Dr. Richter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10 E 102nd St
New York, NY 10029Phone+1 212-241-6756
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
New York Medical College at St Vincent's Hospital and Medical Center of New YorkResidency, Internal Medicine, 2005 - 2008- New York Medical CollegeClass of 2005
Certifications & Licensure
FL State Medical License 2020 - Present
NY State Medical License 2011 - 2025
NJ State Medical License 2011 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Clinical Trials
- Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma Start of enrollment: 2013 Apr 01
- A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 Start of enrollment: 2013 Apr 01
- Myeloma-Developing Regimens Using Genomics (MyDRUG) Start of enrollment: 2019 Apr 01
Roles: Contact
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsVorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple MyelomaElizabeth Bilotti, David H. Vesole, Laura McBride, Linda Schmidt, Zhijie Gao
Clinical Lymphoma, Myeloma & Leukemia. 2016-10-01 - 392 citationsOral selinexor-dexamethasone for triple-class refractory multiple myelomaAjai Chari, Dan T Vogl, Maria Gavriatopoulou, Ajay K. Nooka, Andrew Yee
The New England Journal of Medicine. 2019-08-21 - 14 citationsChromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategiesKamlesh Bisht, Brian A Walker, Shaji Kumar, Ivan Spicka, Philippe Moreau
Expert Review of Hematology. 2021-10-08
Abstracts/Posters
- A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple MyelomaJoshua R Richter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide MaintenanceJoshua Richter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- ADAR1 Drives Disease Progression in Multiple Myeloma By Acting Both As an RNA Editor of Specific Transcripts and As a DNA Mutator of Their Cognate GenesJoshua Richter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplan...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed/refractory multiple myeloma.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
How Bispecific Antibodies Could Make BCMA-Directed Therapy More AccessibleSeptember 20th, 2022- Clinical Challenges: Treatment Options in Waldenström MacroglobulinemiaDecember 17th, 2021
- Clinical Challenges: Signs, Symptoms, and Diagnosis of Waldenström MacroglobulinemiaDecember 10th, 2021
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
